---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-335824"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2025-12-30T23:59:59+00:00"
generated_at: "2026-05-16T11:59:42.497050+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Verrica appoints Charles Frantzreb to board, grants performance-based options to CEO

## Summary
- Charles Frantzreb, Partner at Caligan, appointed to board effective Dec 26, 2025; Class III director term to 2027 annual meeting.
- CEO Jayson Rieger granted options for 512,269 shares at $8.21, vesting on stockholder plan amendment and stock price milestones of $15 and $25.
- Interim CFO John Kirby granted 10,000 fully vested RSUs on Dec 23, 2025.
- Frantzreb designated by Caligan under Securities Purchase Agreement dated Nov 23, 2025.

## SEC filing metadata
- accession: 0001193125-25-335824
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2025-12-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312525335824/0001193125-25-335824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312525335824/d54232d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-335824
- JSON: https://secwatch.observer/filing/0001193125-25-335824.json
- Plain text: https://secwatch.observer/filing/0001193125-25-335824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.